pocketful logo
Syngene International Ltd logo

Syngene International Ltd

NSE: SYNGENE BSE: 539268

₹467.65

(8.21%)

Sat, 09 May 2026, 11:52 am

mtf coin illustrationMTF 5x

Syngene International Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    18454.63

  • Net Profit

    496.20

  • P/B

    6.18

  • Sector P/E

    60.21

  • P/E

    58.89

  • EV/EBITDA

    25.33

  • Debt/Equity (Industry)

    0.41

  • Interest Cover (Industry)

    5.58

  • ROCE (Industry)

    12.45

  • RONW (Industry)

    12.31

  • ROE

    11.05

  • ROCE

    13.37

  • Debt/Equity

    0.13

  • EPS (TTM)

    9.32

  • Dividend Yield

    0.27

  • Book Value

    120.10

  • Interest Cover

    13.43

Analysis

all

thumbs up icon

Pros

  • Performance (ROE) is expected to be above the current IN Life Sciences industry average.
  • Syngene International's revenue growth is expected to exceed the India market average.
  • Syngene International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Syngene International is profitable, therefore cash runway is not a concern.
  • Syngene International is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Syngene International has not reported any payouts.
  • Unable to evaluate Syngene International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Syngene International's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Syngene International's earnings are expected to grow by 1.5% yearly, however this is not considered high growth (20% yearly).
  • Syngene International's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters52.6852.6852.6852.6852.74
FII13.9014.9616.3116.5019.47
DII26.4425.8424.6224.0521.50
Public6.986.526.386.776.29
Government00000

Read More

Technical Analysis

RSI

57.31

MACD

11.39

50 DMA

421.26

200 DMA

573.97

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic732.50593.95530.80455.40392.25316.85178.30
Fibonacci593.95541.02508.33455.40402.47369.78316.85
Camarilla505.75493.05480.35455.40454.95442.25429.55

Pivots Level: Classic

R3

+277.10

732.50

R2

+138.55

593.95

R1

+75.40

530.80

455.40
455.40
Pivot Point
LTP: 458.10

S1

-63.15

392.25

S2

-138.55

316.85

S3

-277.10

178.30

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    451.64

  • 20-EMA

    440.96

  • 30-EMA

    436.84

  • 50-EMA

    443.60

  • 100-EMA

    483.26

  • 200-EMA

    547.10

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 Apr 2026board-meetingsAccounts, Final Dividend
29 Apr 2026dividend₹1.25 Dividend /Share26 Jun 2026
29 Apr 2026agm
22 Jan 2026board-meetingsQuarterly Results
05 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
27 May 2025dividendFinal Dividend - Rs. - 1.2527 Jun 2025
23 Apr 2025dividend₹1.25 Dividend /Share27 Jun 2025
23 Apr 2025agm
28 May 2024dividendFinal Dividend - Rs. - 1.2528 Jun 2024
24 Apr 2024dividend₹1.25 Dividend /Share28 Jun 2024

Read More

Peer Comparison

Syngene International Ltd logo

Syngene International Ltd

Max Healthcare Institute Ltd logo

Max Healthcare Institute Ltd

Narayana Hrudayalaya Ltd logo

Narayana Hrudayalaya Ltd

Aster DM Healthcare Ltd logo

Aster DM Healthcare Ltd

Fortis Healthcare Ltd logo

Fortis Healthcare Ltd

Apollo Hospitals Enterprise Ltd logo

Apollo Hospitals Enterprise Ltd

Read More

Syngene International Ltd About

Syngene International is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Syngene’s services include integrated drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.

Industry

Miscellaneous

Founded

1993

Headquarters

CEO

Kiran Mazumdar Shaw

Employees

Contact

Website icon

Website

http://www.syngeneintl.com

Email icon

Email

investor@syngeneintl.com; Mayank.Verma@syngeneintl

Phone icon

Phone

91-80-68915000/67758781

Location icon

Location

Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds, Bengaluru, Karnataka, 560099

Read More

Syngene International Ltd Company History

YearHistory
2020
  • Syngene ties up with HiMedia Laboratories to manufacture ELISA test kits for COVID-19.
  • Syngene joins global industry consortium to accelerate collaborative research in COVID-19 testing.
  • Syngene and PharmAust collaborate to manufacture GMP-grade Monepantel for Human Clinical Trials.
  • Bioprocessing Excellence Award 2020.
2021
  • Syngene receives India Pharma Awards 2021.
  • Syngene Ranked As One Of The Top 100 Indian Wealth Creators For 2021.
  • Syngene International extends long term research collaboration with Bristol Myers Squibb until 2030.
  • Syngene through Biocon Foundation partners with NIMHANS for BHUMI.
2022
  • Syngene International takes top honors at CMO Leadership Awards 2022 for contract manufacturing.
  • Syngene signs 10-year biologics manufacturing agreement with leading animal health company.
  • Syngene and the Research and Innovation Circle of Hyderabad (RICH) launch scholarship program for women studying STEM subjects.
2023
  • Winner of India's Best Managed Companies 2023 programme
  • Supply Chain Champion Award, 2023
  • Best Overall Sustainable Performance (Pharmaceutical) 2023
  • Biopharma Excellence Award (India Edition) 2023
  • Panbela announces issuance of new patent in Australia.
2024
  • Syngene received Pharmaceutical Technology Excellence Awards 2024.
  • Syngene received Asia Pacific Biologics CMO Excellence Awards 2024.
  • Syngene awarded CDMO Leadership Awards 2024.
  • Syngene secures silver rating in EcoVadis sustainability index, ranking in top 15% of assessed companies.
  • Syngene launches platform for rapid, enhanced protein production.
  • Syngene International named as one of India's Best Managed Companies by Deloitte India.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy2160599486.430 Apr 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDSell2160599486.6230 Apr 2026
MICROCURVES TRADING PRIVATE LIMITEDBuy2766287481.930 Apr 2026
MICROCURVES TRADING PRIVATE LIMITEDSell2766287482.0230 Apr 2026
BIOCON LIMITEDSell8000000857.6810 Dec 2024
BIOCON LIMITEDSell4000000056001 Feb 2023
GOVERNMENT OF SINGAPOREBuy1579920056001 Feb 2023
BIOCON LIMITEDSell4000000056002 Jan 2023
GOVERNMENT OF SINGAPOREBuy1579920056002 Jan 2023
BIOCON LIMITEDSell21789164560.0406 Sept 2022

Read More

Syngene International Ltd News

Syngene Q4 FY26 Earnings Call Transcript Now Available

Syngene International filed Q4 FY26 earnings call transcript under Regulation 30. Q4 revenue rose 2% to Rs 10,365 million, while PAT fell 19% YoY to Rs 1,479 million.

05 May 2026

companies

Syngene Q4 FY26: Revenue Rises, Profit Falls

Syngene International reported Q4 FY26 revenue of Rs 10,365 million (+2% YoY) with consolidated PAT at Rs 1,479 million (-19% YoY). EBITDA margin declined to 30.8% from 35.0%. Board recommended final dividend of Rs 1.25 per share.

02 May 2026

companies

Syngene Q4 FY26: Revenue Rises, Profit Falls

Syngene International reported Q4 FY26 revenue of Rs 10,365 million (+2% YoY) with consolidated PAT at Rs 1,479 million (-19% YoY). EBITDA margin declined to 30.8% from 35.0%. Board recommended final dividend of Rs 1.25 per share.

01 May 2026

companies

Syngene Q4 FY26: Revenue Grows, Profit Declines

Syngene International reported Q4 FY26 revenue of Rs 1,037 crore (+2% YoY) with PAT before exceptional items at Rs 153 crore (-16% YoY). Operating EBITDA margin declined to 29% from 34% in Q4 FY25. Key management changes announced with Kiran Mazumdar-Shaw transitioning to Executive Chairperson.

01 May 2026

companies

Syngene International Block Trade Worth ₹41.20 Cr

Syngene International witnessed a significant NSE block trade of ₹41.20 crores involving approximately 797,278 shares at ₹516.80 per share, indicating substantial institutional activity.

30 Apr 2026

equity-markets

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800